[Current screening for molecular target therapy of cancer].
Recent progress in molecular biology and cancer biology has revealed that many molecules, which are heavily involved in the un-limited growth, anti-apoptotic effects and invasion of tumors, would be targets of cancer therapy. Part of the drugs which inhibit these molecules have shown clinical response as well as clinical benefits. In this review article, the summary of mechanism based drug screening for cancer as well as recent status of new molecular target drugs for cancer, are described.
Shiotsu
Yukimasa
Y
Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd, 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731, Japan.
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides; D001897:Boronic Acids / Q000494:pharmacology; D000069286:Bortezomib; D016503:Drug Delivery Systems; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D000077156:Gefitinib; D006360:Heat-Shock Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000494:pharmacology; D007783:Lactones / Q000494:pharmacology; D051379:Mice; D009369:Neoplasms / Q000235:genetics / Q000473:pathology; D010793:Phthalazines / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D011719:Pyrazines / Q000494:pharmacology; D011725:Pyridines; D011743:Pyrimidines / Q000494:pharmacology; D011758:Pyrroles / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology; D000077210:Sunitinib
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001549:Benzamides; D001897:Boronic Acids; D006360:Heat-Shock Proteins; D007211:Indoles; C456099:KF58333; D007783:Lactones; D010793:Phthalazines; D010879:Piperazines; D010880:Piperidines; D011719:Pyrazines; D011725:Pyridines; D011743:Pyrimidines; D011758:Pyrroles; D011799:Quinazolines; C404768:vatalanib; D000069286:Bortezomib; D000068877:Imatinib Mesylate; D000077156:Gefitinib; D000077210:Sunitinib; C452423:vandetanib